|Toxiciy Grade:||3||City/State/Province:||Vancouver, B.C.|
|Treatments:||Chemotherapy, Biologic therapy||Hospital:||Vancouver Cancer Centre|
Patients: This Phase II trial involved a total of 30 women with HER-2 overexpressing metastatic breast cancer.
Treatment: The treatment consisted of chemotherapy (pegylated liposomal doxorubicin) and biological therapy trastuzumab (herceptin) a type of monoclonal antibody.
Toxicity: Grade 3-4 toxicities included mucositis, hand-foot syndrome, and neutropenia.
Results: The authors report that at a median follow-up of 13.9 months, the median progression-free survival was 12.0 months and the median overall survival has not yet been reached.
Support: One author was an employee of Schering Canada. Another was a consultant with Schering Plough and had received honoraria from Schering Plough and Hoffman la Roche. Three more authors received honoraria from Roche, Hoffman LaRoche and Genetech, and Schering Canada.
Correspondence: Stephen Chia, MD